TY - JOUR
T1 - Neoantigen activation, protein translocation and targeted drug delivery in combination with radiotherapy
AU - Sethuraman, Sri Nandhini
AU - Ranjan, Ashish
N1 - Publisher Copyright:
© 2016 Future Science Ltd.
PY - 2016/6
Y1 - 2016/6
N2 - Concurrent chemo and radiation therapies are commonly used to treat locally advanced cancer. Despite improved efficacy, failure rates remain high due to healthy organ toxicity caused by chemo-radiotherapy. Recent technological advances such as nanoparticle encapsulation of anticancer agents, locally controlled irradiation and concurrent use of radio- and nano-medicines are providing innovative solutions for overcoming the limitations of systemic and local treatment toxicities. In this mini-review, we discuss the roles of radiotherapy in generating new therapeutic targets and altering the tumor microenvironment, and we propose their future applications in drug delivery in combination with radiotherapy.
AB - Concurrent chemo and radiation therapies are commonly used to treat locally advanced cancer. Despite improved efficacy, failure rates remain high due to healthy organ toxicity caused by chemo-radiotherapy. Recent technological advances such as nanoparticle encapsulation of anticancer agents, locally controlled irradiation and concurrent use of radio- and nano-medicines are providing innovative solutions for overcoming the limitations of systemic and local treatment toxicities. In this mini-review, we discuss the roles of radiotherapy in generating new therapeutic targets and altering the tumor microenvironment, and we propose their future applications in drug delivery in combination with radiotherapy.
KW - neoantigen activation
KW - radiation therapy
KW - radiation triggered drug release
UR - http://www.scopus.com/inward/record.url?scp=84978496249&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84978496249&partnerID=8YFLogxK
U2 - 10.4155/tde-2016-0005
DO - 10.4155/tde-2016-0005
M3 - Review article
C2 - 27250535
AN - SCOPUS:84978496249
SN - 2041-5990
VL - 7
SP - 377
EP - 385
JO - Therapeutic Delivery
JF - Therapeutic Delivery
IS - 6
ER -